McKesson CorporationMCKNYSE
Loading
McKesson is North America's largest pharmaceutical distributor, operating a low-margin, high-volume logistics network that moves ~30% of all prescription drugs in the U.S. and Canada. The company generates value through scale advantages in procurement, distribution density across 13,000+ pharmacies, and specialty pharmacy services for oncology and rare disease medications. Stock performance is driven by prescription volume growth, generic drug sourcing margins, and the company's ability to extract operational efficiency from its massive distribution infrastructure.
McKesson operates a scale-driven logistics arbitrage: purchasing pharmaceuticals in bulk from manufacturers at negotiated discounts, then distributing through 44 distribution centers with 99.9%+ fill rates. Profitability comes from (1) manufacturer service fees for distribution and data services, (2) generic drug sourcing spreads through ClarusONE Sourcing venture (buying generics 15-20% below market), (3) specialty pharmacy margins of 8-12% on high-cost oncology/biotech drugs requiring cold chain logistics, and (4) technology platform fees from 14,000+ independent pharmacies. The 0.88 current ratio reflects negative working capital dynamics where McKesson collects from customers faster than it pays suppliers—a cash conversion advantage generating $6.1B operating cash flow on $359B revenue.
Generic drug launch pipeline and sourcing spread capture through ClarusONE venture (every 100bps improvement in generic margin drives $1.5B+ gross profit)
Prescription volume trends driven by Medicare Part D enrollment growth (10,000 Americans turn 65 daily) and GLP-1 obesity drug adoption
Specialty pharmacy revenue growth, particularly oncology biosimilar penetration and CAR-T cell therapy distribution requiring specialized handling
Contract renewals with top 5 customers representing 40%+ of revenue (Walmart, CVS retail, Rite Aid, Kroger pharmacies)
Opioid litigation settlement costs and timing (company faces $8B+ in potential liabilities)
Share repurchase activity enabled by $5.2B annual free cash flow (company retired 5% of shares outstanding in past year)
Vertical integration by PBMs and payers (CVS/Aetna owns retail pharmacies and PBM, eliminating distributor role for 25% of market)
Amazon Pharmacy expansion and potential direct-to-consumer pharmaceutical delivery disrupting traditional distribution economics
Drug pricing reform legislation (Medicare negotiation, importation from Canada) compressing manufacturer revenues and reducing service fees paid to distributors
Biosimilar adoption accelerating shift to lower-margin specialty products as patents expire on high-margin biologics
Duopoly market structure with AmerisourceBergen (now Cencora) creates intense competition for contract renewals, limiting pricing power
Cardinal Health competing aggressively in Medical-Surgical segment with overlapping customer base
Manufacturer direct distribution models bypassing wholesalers for specialty pharmaceuticals requiring unique handling
Negative equity of -$28.3B driven by $35B+ in share repurchases over past decade, creating -245% ROE and -6.64 debt/equity ratio (financial engineering risk)
Opioid litigation exposure with $8B+ in potential settlement costs beyond $1.6B already accrued
Pension obligations and retiree healthcare liabilities for 78,000-person workforce with aging demographics
Customer concentration risk with top 10 customers representing 60%+ of revenue—loss of single large contract materially impacts profitability
low - Pharmaceutical demand is highly inelastic with 90% of prescriptions covered by insurance (Medicare, Medicaid, commercial). Recession impact is minimal as people continue taking maintenance medications. However, elective procedures and physician office visits (affecting Medical-Surgical segment) show moderate GDP sensitivity. Unemployment increases Medicaid enrollment, which has lower reimbursement rates but higher volume.
Rising rates have moderate negative impact through two channels: (1) $7.6B net debt position increases interest expense by ~$75M per 100bps rate increase, and (2) higher discount rates compress valuation multiples for stable cash flow businesses trading at 18.7x EV/EBITDA. However, negative working capital model means McKesson earns float income on cash held between supplier payment and customer collection cycles. Offsetting factor: rate increases often correlate with stronger economy driving elective procedure volumes.
Moderate exposure to customer credit quality as McKesson extends payment terms to independent pharmacies and small hospital systems. Tightening credit conditions increase bad debt reserves and reduce willingness to extend favorable terms. However, 60% of revenue comes from investment-grade rated customers (large chains, hospital systems). Generic drug sourcing requires supplier financing, so McKesson's own credit rating (BBB+) affects procurement costs.
value - Stock trades at 0.3x sales and generates 4.5% FCF yield, attracting investors focused on cash generation and capital returns. The 55% one-year return reflects multiple expansion as market recognized recession-resistant earnings and aggressive buyback program. Negative book value and financial engineering create controversy, splitting value investors between those focused on cash flow vs. balance sheet quality.
low - Beta approximately 0.6-0.7 given defensive healthcare exposure and stable prescription demand. However, litigation headlines and contract renewal announcements create episodic volatility. Stock exhibits lower volatility than S&P 500 during market downturns but lags in strong bull markets due to low growth profile.